1 1
2011 Full Year Results
28th February, 2012
2011 Full Year Results 28 th February, 2012 1 1 Disclaimer This - - PowerPoint PPT Presentation
2011 Full Year Results 28 th February, 2012 1 1 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking
1 1
28th February, 2012
2
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements" and are based on the Company's current
to: the success of the Company’s research strategy; the applicability of discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether the Company’s potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from the government, private healthcare insurers and third-party payers; and the uncertainties as to the extent of future government regulation of the pharmaceutical business. Therefore, those statements involve risks and uncertainties beyond the Company's control and consequently actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.
3
steady Yondelis sales
– Reimbursement agreements continue to progress globally – New agreement totalling US$110 million signed with Jansen in December to intensify development of Yondelis in USA – Yondelis granted orphan drug status in Japan for soft tissue sarcoma – Sales growth impeded by European macro economic weakness
– Aplidin: Recruitment complete for phase III pivotal trial for the treatment of Relapsed Multiple Myeloma – PM01183: Recruitment commenced for 2x phase II trials in pancreatic cancer and platinum-refractory/resistant ovarian cancer – Tideglusib/Nypta: Recruitment complete for ARGO trial in Alzheimer’s disease. – RNAi: Phase I trial commenced for 2nd product (SYL1001) for dry eye syndrome
down 2.76% at €71.2m)
4
5
11%
€ / millions
5
72,3 74,2 7,1 6,5
10 20 30 40 50 60 70 80 90 2010 2011
Pharmamar Genómica
BioPharma Segment Consumer Chemical Segment
56 54,3 17,2 17
10 20 30 40 50 60 70 80 2010 2011
Zelnova Xylazel 72,3 74,2 7,1 6,5
10 20 30 40 50 60 70 80 90 2010 2011
Pharmamar Genómica
2011
€ / millions € / millions
6
€ / millions
BioPharma Consumer Chemicals
7
€ / millions
8
55,7 56,7 42,8 43,5 19,3 21,9 8,6 9,2
20 40 60 80 100 120 140 2010 2011
R&D Sales & Marketing G&A Other
€ / millions
9
€ / millions
10
13,2
5 10 15 2009 2010 2011
€ / millions
11
4,7
2008 2009 2010 2011 50 100 150 2007 2008 2009 2010 2011 Sales Net Attributable Result
€ / millions
12
13
interest-free R&D loans
€52.7m
lending leads to favourable debt structure lowering interest rates
€49.3m
Evolution of Debt Levels
85,3 83,1 62,9 52,7 25 50 75 100 125 2010 2011
Long term debt Short term debt
€m
– Continued growth in Yondelis sales in Europe – Potential approval in Europe for generic of Doxil – Jansen agreement provides new impetus for Yondelis in US
in importance for the Group
– Multiple pipeline assets progressing through the clininc
14
1 1
28th February, 2012
2
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements" and are based on the Company's current
to: the success of the Company’s research strategy; the applicability of discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether the Company’s potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from the government, private healthcare insurers and third-party payers; and the uncertainties as to the extent of future government regulation of the pharmaceutical business. Therefore, those statements involve risks and uncertainties beyond the Company's control and consequently actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.
3
steady Yondelis sales
– Reimbursement agreements continue to progress globally – New agreement totalling US$110 million signed with Jansen in December to intensify development of Yondelis in USA – Yondelis granted orphan drug status in Japan for soft tissue sarcoma – Sales growth impeded by European macro economic weakness
– Aplidin: Recruitment complete for phase III pivotal trial for the treatment of Relapsed Multiple Myeloma – PM01183: Recruitment commenced for 2x phase II trials in pancreatic cancer and platinum-refractory/resistant ovarian cancer – Tideglusib/Nypta: Recruitment complete for ARGO trial in Alzheimer’s disease. – RNAi: Phase I trial commenced for 2nd product (SYL1001) for dry eye syndrome
down 2.76% at €71.2m)
4
5
11%
€ / millions
5
72,3 74,2 7,1 6,5
10 20 30 40 50 60 70 80 90 2010 2011
Pharmamar Genómica
BioPharma Segment Consumer Chemical Segment
56 54,3 17,2 17
10 20 30 40 50 60 70 80 2010 2011
Zelnova Xylazel 72,3 74,2 7,1 6,5
10 20 30 40 50 60 70 80 90 2010 2011
Pharmamar Genómica
2011
€ / millions € / millions
6
€ / millions
BioPharma Consumer Chemicals
7
€ / millions
8
55,7 56,7 42,8 43,5 19,3 21,9 8,6 9,2
20 40 60 80 100 120 140 2010 2011
R&D Sales & Marketing G&A Other
€ / millions
9
€ / millions
10
13,2
5 10 15 2009 2010 2011
€ / millions
11
4,7
2008 2009 2010 2011 50 100 150 2007 2008 2009 2010 2011 Sales Net Attributable Result
€ / millions
12
13
interest-free R&D loans
€52.7m
lending leads to favourable debt structure lowering interest rates
€49.3m
Evolution of Debt Levels
85,3 83,1 62,9 52,7 25 50 75 100 125 2010 2011
Long term debt Short term debt
€m
– Continued growth in Yondelis sales in Europe – Potential approval in Europe for generic of Doxil – Jansen agreement provides new impetus for Yondelis in US
in importance for the Group
– Multiple pipeline assets progressing through the clininc
14